Back to top
more

Assertio (ASRT)

(Delayed Data from NSDQ)

$0.84 USD

0.84
325,501

+0.01 (0.85%)

Updated Oct 13, 2025 04:00 PM ET

After-Market: $0.84 0.00 (-0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (77 out of 243)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is the Options Market Predicting a Spike in Assertio (ASRT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Zacks Equity Research

Assertio (ASRT) Q2 Earnings Miss Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -7.14% and 3.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 50% and 3.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aquestive (AQST) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues.

Zacks Equity Research

Assertio (ASRT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -153.85% and 12.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Assertio (ASRT) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Assertio (ASRT) closed at $5.08, marking a +1.6% move from the previous day.

Zacks Equity Research

Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Assertio Therapeutics' (ASRT) Q1 earnings call, investors will likely focus on the sales performance of its rheumatology, pain and inflammation medicines.

Zacks Equity Research

Investors Heavily Search Assertio Holdings, Inc. (ASRT): Here is What You Need to Know

by Zacks Equity Research

Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

Assertio (ASRT) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Assertio (ASRT) closed the most recent trading day at $6.01, moving +1.01% from the previous trading session.

Zacks Equity Research

Assertio (ASRT) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Assertio (ASRT) closed at $6.30, marking a +0.64% move from the previous day.

Zacks Equity Research

Here is What to Know Beyond Why Assertio Holdings, Inc. (ASRT) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Assertio (ASRT) closed at $5.78 in the latest trading session, marking a -0.86% move from the prior day.

Zacks Equity Research

Is Trending Stock Assertio Holdings, Inc. (ASRT) a Buy Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

Assertio (ASRT) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of 482.61% and 1.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 16.48% and 46.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alaunos (TCRT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Alaunos Therapeutics (TCRT) is expected to provide an update on its pipeline candidates, Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy, in its fourth-quarter earnings.

Zacks Equity Research

Assertio Holdings, Inc. (ASRT) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

The Cooper Companies (COO) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

The Cooper Companies (COO) delivered earnings and revenue surprises of 9.02% and 2.93%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Oncternal Therapeutics (ONCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Earnings Season Could Be Great for Assertio (ASRT)

by Zacks Equity Research

Assertio (ASRT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Assertio (ASRT) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Assertio (ASRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Assertio (ASRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Cronos Group (CRON) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cronos (CRON) delivered earnings and revenue surprises of -180% and 7.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

FibroGen (FGEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of 26.32% and 43.89%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.